Company intelligence / Profile preview

Biolytics Pharma

Birkerød, Denmark

Ownership: Private
Development stage: Other

Overview

Biolytics Pharma is a Danish early-stage biotech company focused on developing bacteriophage-based anti-infectives for severe multidrug-resistant Gram-negative bacterial infections. The company is developing complex bacteriophage formulations, referred to as BIOLYTICALS, aimed at pathogens including Pseudomonas and Klebsiella. Available company-profile sources describe it as operating as a virtual company, relying heavily on CROs for research and strategic development activities. Biolytics Pharma appears to be a private, active company founded in 2012 and based in the Copenhagen/Birkerød area of Denmark.

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophage therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Biolytics Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biolytics Pharma.

Explore the full profile